MedElevator Войти в исследования
← Поиск публикаций

DOI 10.59556/japi.72.0543

Медицинская библиотека · The Journal of the Association of Physicians of India · 2024

Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.

Chopra H K, Khullar Dinesh, Nair Tiny, Wander G S, Ponde C K, Ray Saumitra, Nanda Navin C, Kasliwal Ravi R, Rana D S, Kirpalani Ashok, Sawhney Jps, Chandra Praveen, Mehta Yatin, Kumar Viveka, Tewari S, Pancholia A K, Kher Vijay, Bansal Sandeep, Mittal Sanjay, Kerkar Praful, Sahoo P K, Hotchandani Ramesh, Prakash Sunil, Chauhan Nagendra, Rastogi Vishal, Jabir A, Shanmugasundaram S, Tiwaskar Mangesh, Sinha Ajay, Gupta Vittul, Mishra S S, Routray S N, Omar A K, Swami Onkar C, Jaswal Aparna, Alam Shamsad, Passey Rajeev, Rajput Rajeeve, Paul Justin, Kapoor Aditya, Prabhakar D, Chandra Subhash, Malhotra Poonam, Singh Vivudh Pratap, Bansal Manish, Shah Priyank, Jain Sanjay, Bhargava Mohan, Vijayalakshmi I B, Varghaese Kiron, Jain Dharmender, Goel Anupam, Gaur Namrata, Tandon Rohit, Moorthy Asha, George Sheeba, Katyal V K, Mantri R R, Mehrotra Rahul, Bhalla Dilip, Mittal Vinod, Rao Sarita, Jagia Manish, Singh Harmeet, Awasthi Surabhi, Sattur Ameet, Mishra Rekha, Pandey Anand, Chawla Rajeev, Jaggi Shalini, Sehgal Blessy, Sehgal Alok, Goel Naresh, Gupta Ripen, Kubba Samir, Chhabra Abhinav, Bagga Saurabh, Shastry N R

СтатьяConsensus StatementПеревод в очереди

Аннотация

Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in India. CKD often coexists with heart failure (HF), diabetes, and hypertension. All these comorbidities are risk factors for renal impairment. HF and CKD are pathophysiologically intertwined, and the deterioration of one can worsen the prognosis of the other. There is a need for safe renal pharmacological therapies that target both CKD and HF and are also useful in hypertension and diabetes. Neurohormonal activation achieved through the activation of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS), and the natriuretic peptide system (NPS) is fundamental in the pathogenesis and progression of CKD and HF. Angiotensin receptor neprilysin inhibitor (ARNi), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), and selective β1-blocker (B1B) bisoprolol suppress this neurohormonal activation. They also have many other cardiorenal benefits across a wide range of CKD patients with or without concomitant HF, diabetes, or hypertension. This consensus statement from India explores the place of ARNi, SGLT-2i, and bisoprolol in the management of CKD patients with or without HF and other comorbidities.

Для цитирования: Chopra H K, Khullar Dinesh, Nair Tiny, Wander G S, Ponde C K, Ray Saumitra, Nanda Navin C, Kasliwal Ravi R, Rana D S, Kirpalani Ashok, Sawhney Jps, Chandra Praveen, Mehta Yatin, Kumar Viveka, Tewari S, Pancholia A K, Kher Vijay, Bansal Sandeep, Mittal Sanjay, Kerkar Praful, Sahoo P K, Hotchandani Ramesh, Prakash Sunil, Chauhan Nagendra, Rastogi Vishal, Jabir A, Shanmugasundaram S, Tiwaskar Mangesh, Sinha Ajay, Gupta Vittul, Mishra S S, Routray S N, Omar A K, Swami Onkar C, Jaswal Aparna, Alam Shamsad, Passey Rajeev, Rajput Rajeeve, Paul Justin, Kapoor Aditya, Prabhakar D, Chandra Subhash, Malhotra Poonam, Singh Vivudh Pratap, Bansal Manish, Shah Priyank, Jain Sanjay, Bhargava Mohan, Vijayalakshmi I B, Varghaese Kiron, Jain Dharmender, Goel Anupam, Gaur Namrata, Tandon Rohit, Moorthy Asha, George Sheeba, Katyal V K, Mantri R R, Mehrotra Rahul, Bhalla Dilip, Mittal Vinod, Rao Sarita, Jagia Manish, Singh Harmeet, Awasthi Surabhi, Sattur Ameet, Mishra Rekha, Pandey Anand, Chawla Rajeev, Jaggi Shalini, Sehgal Blessy, Sehgal Alok, Goel Naresh, Gupta Ripen, Kubba Samir, Chhabra Abhinav, Bagga Saurabh, Shastry N R. Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.. The Journal of the Association of Physicians of India. 2024. DOI: 10.59556/japi.72.0543.

Предметные рубрики MeSH

HumansRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsIndiaBisoprololAngiotensin Receptor AntagonistsAdrenergic beta-1 Receptor Antagonists
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.